Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Dasatinib in CML and Ph+ ALL
NCT01030718Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2006
- Primary completion
- Jun 2009
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML), Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Bristol Myers Squibb. Started Jan 2006; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT01030718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01030718.